Pharmacology, Toxicology and Pharmaceutical Science
Proteasome Inhibitor
100%
Peptide
100%
Anticarcinogen
100%
Bortezomib
72%
Multiple Myeloma
63%
Carfilzomib
63%
Malignant Neoplasm
54%
Proteasome
36%
Lead
18%
Drug Resistance
18%
Drug
18%
Pharmacokinetics
18%
Animal
9%
Intrinsic Resistance
9%
Lead Compounds
9%
Tumor Growth
9%
Enzyme Kinetics
9%
Toxicity
9%
Drug Delivery System
9%
Cross-Resistance
9%
Biochemistry, Genetics and Molecular Biology
Proteasome Inhibitor
100%
Peptide
100%
Solid
45%
Proteasome
36%
Drug Resistance
18%
Pharmacokinetics
18%
Antineoplastic Activity
18%
Exercise
9%
Growth
9%
Cross Resistance
9%
Preclinical Study
9%
Motivation
9%
Drug Targeting
9%
Animal Models
9%
Synthesis
9%
Pharmacophore
9%
Development
9%
Enzyme Kinetics
9%